Police & Firemen s Retirement System of New Jersey Trims Holdings in Stryker Corporation $SYK

Police & Firemen s Retirement System of New Jersey cut its stake in Stryker Corporation (NYSE:SYK) by 0.8% during the 2nd quarter, HoldingsChannel reports. The fund owned 52,292 shares of the medical technology company’s stock after selling 404 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in Stryker were worth $20,688,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Consolidated Portfolio Review Corp lifted its holdings in Stryker by 4.2% during the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock worth $256,000 after buying an additional 26 shares during the last quarter. Princeton Global Asset Management LLC boosted its holdings in Stryker by 16.9% in the second quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after purchasing an additional 26 shares during the period. Sunflower Bank N.A. increased its stake in Stryker by 4.0% during the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after purchasing an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC lifted its position in shares of Stryker by 3.2% in the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock worth $341,000 after buying an additional 27 shares during the last quarter. Finally, Sachetta LLC grew its position in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 520,500 shares of company stock valued at $184,803,065 in the last quarter. 5.20% of the stock is currently owned by corporate insiders.

Stryker Stock Up 1.1%

SYK stock opened at $367.65 on Thursday. The firm has a market cap of $140.60 billion, a PE ratio of 48.70, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm has a 50 day simple moving average of $372.98 and a 200 day simple moving average of $381.24.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. UBS Group set a $408.00 price target on Stryker in a report on Monday, October 13th. Redburn Partners set a $420.00 price target on shares of Stryker in a research note on Thursday, September 18th. Rothschild Redb raised Stryker to a “hold” rating in a research note on Thursday, September 18th. Truist Financial reaffirmed a “hold” rating and issued a $392.00 price objective (down previously from $407.00) on shares of Stryker in a report on Monday, November 3rd. Finally, Evercore ISI decreased their price objective on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $433.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.